(Total Views: 853)
Posted On: 08/24/2020 4:00:52 PM
Post# of 155836
Re: clambottler #51968
Quote:
Conclusion
The relationships between mortality and both time to plasma transfusion, and antibody levels provide a signature that is consistent with efficacy for the use of convalescent plasma in the treatment of hospitalized COVID-19 patients.
Conclusion: The successful P2 trial of Leronlimab with Per Protocol Population in a double-blinded clinical trial yielded statistically significant p-values for NEWS2 scores of p<0.03 and p<0.02 at 3 and 14 days respectively that is consistent with efficacy for the use of Mild-to Moderate COVID patients.
(3)
(0)
